Raleigh Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Raleigh Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-185	Closed	-$3.72K	–	1087
2023 Q3	$3.72K	Hold	185	–	–	﹤0.01%	729
2023 Q2	$4.72K	Buy	+185	New	+$4.3K	﹤0.01%	653

Other funds holding BCYC

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Raleigh Capital Management's BCYC Position: Q4 2023 in Review

Raleigh Capital Management sold out of Bicycle Therapeutics (BCYC) in Q4 2023, closing a stake of 185 shares — an estimated $3.72K sold.

Raleigh Capital Management first reported a position in BCYC in Q2 2023 and held it in 2 quarters. The position peaked at $4.72K in Q2 2023. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

Raleigh Capital Management reported no remaining Bicycle Therapeutics position as of Q4 2023 after selling out during the quarter.
Raleigh Capital Management sold 185 Bicycle Therapeutics shares in Q4 2023, an estimated $3.72K.
Raleigh Capital Management first reported a position in Bicycle Therapeutics in Q2 2023 and held it in 2 quarters.
Raleigh Capital Management's Bicycle Therapeutics position peaked at $4.72K in Q2 2023.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on Raleigh Capital Management's 13F filing for Q4 2023, filed 21 Feb 2024.